{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"Provider will assess study subject for severity of cGVHD per 2014 NIH consensus criteria at day 92.","groups":[{"description":"1 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG000","title":"Dose Level: 0"},{"description":"3 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG001","title":"Dose Level: 1"},{"description":"10 mg/kg of Ipilimumab and 3x10\\^7 CD3+ cells/kg of CD25/Treg-depleted DLI will be administered intravenously over 90 ± 10 minutes after the DLI product observation period is completed, and dosing will continue in 3-week intervals for 4 cycles, unless unacceptable toxicity or symptomatic disease progression occurs.","id":"OG002","title":"Dose Level: 2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 92","title":"Incidence of Chronic GVHD Rates","type":"SECONDARY","unitOfMeasure":"Participants"}